Evidence map›Paper›PMID 35783606›Full record

ArticleFrontiers in medicine2022

SARS-CoV-2 Viremia Precedes an IL6 Response in Severe COVID-19 Patients: Results of a Longitudinal Prospective Cohort.

Emilia Roy-Vallejo, Laura Cardeñoso, Ana Triguero-Martínez, Marta Chicot Llano, Nelly Zurita, Elena Ávalos, Ana Barrios, Julia Hernando, Javier Ortiz, Sebastián C Rodríguez-García and 28 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 1 institution in 1 country.

Emilia Roy-VallejoDepartment of Internal Medicine, Hospital Universitario La Princesa, Madrid, Spain.
Laura CardeñosoDepartment of Microbiology, Hospital Universitario La Princesa, Madrid, Spain.
Ana Triguero-MartínezDepartment of Rheumatology, Hospital Universitario La Princesa, Madrid, Spain.
Marta Chicot LlanoIntensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain.
Nelly ZuritaDepartment of Microbiology, Hospital Universitario La Princesa, Madrid, Spain.
Elena ÁvalosDepartment of Pneumology, Hospital Universitario La Princesa, Madrid, Spain.
Ana BarriosDepartment of Internal Medicine, Hospital Universitario La Princesa, Madrid, Spain.
Julia HernandoDepartment of Anesthesiology, Hospital Universitario La Princesa, Madrid, Spain.
Javier OrtizDepartment of Hematology, Hospital Universitario La Princesa, Madrid, Spain.
Sebastián C Rodríguez-GarcíaDepartment of Rheumatology, Hospital Universitario La Princesa, Madrid, Spain.
Marianela Ciudad SañudoDepartment of Internal Medicine, Hospital Universitario La Princesa, Madrid, Spain.
Celeste MarcosDepartment of Pneumology, Hospital Universitario La Princesa, Madrid, Spain.
Elena García CastilloDepartment of Pneumology, Hospital Universitario La Princesa, Madrid, Spain.
Leticia Fontán García-RodrigoDepartment of Microbiology, Hospital Universitario La Princesa, Madrid, Spain.
Begoña GonzálezIntensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain.
Rosa MéndezDepartment of Anesthesiology, Hospital Universitario La Princesa, Madrid, Spain.
Isabel IturrateDepartment of Hematology, Hospital Universitario La Princesa, Madrid, Spain.
Ancor Sanz-GarcíaMethodology Unit, Health Research Institute, Hospital Universitario La Princesa, IIS-IP, Madrid, Spain.
Almudena VillaDepartment of Internal Medicine, Hospital Universitario La Princesa, Madrid, Spain.
Ana Sánchez-AzofraDepartment of Pneumology, Hospital Universitario La Princesa, Madrid, Spain.
Begoña QuiciosIntensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain.
David ArribasDepartment of Anesthesiology, Hospital Universitario La Princesa, Madrid, Spain.
Jesús Álvarez RodríguezDepartment of Internal Medicine, Hospital Universitario La Princesa, Madrid, Spain.
Pablo PatiñoIntensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain.
Marina TriguerosIntensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain.
Miren UriarteDepartment of Rheumatology, Hospital Universitario La Princesa, Madrid, Spain.
Alexandra Martín-RamírezDepartment of Microbiology, Hospital Universitario La Princesa, Madrid, Spain.
Cristina Arévalo RománDepartment of Internal Medicine, Hospital Universitario La Princesa, Madrid, Spain.
José María Galván-RománDepartment of Internal Medicine, Hospital Universitario La Princesa, Madrid, Spain.
Rosario García-VicuñaDepartment of Rheumatology, Hospital Universitario La Princesa, Madrid, Spain.
Julio AncocheaDepartment of Pneumology, Hospital Universitario La Princesa, Madrid, Spain.
Cecilia Muñoz-CallejaDepartment of Immunology, Hospital Universitario La Princesa, Madrid, Spain.
Elena Fernández-RuizMolecular Biology Unit, Hospital Universitario La Princesa, Madrid, Spain.
Rafael de la CámaraDepartment of Hematology, Hospital Universitario La Princesa, Madrid, Spain.
Carmen Suárez FernándezDepartment of Internal Medicine, Hospital Universitario La Princesa, Madrid, Spain.
Isidoro González-ÁlvaroDepartment of Rheumatology, Hospital Universitario La Princesa, Madrid, Spain.
Diego A Rodríguez-SerranoIntensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain.
PREDINMUN-COVID Group
Hospital Universitario de La Princesa · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Interleukin 6 (IL6) levels and SARS-CoV-2 viremia have been correlated with COVID-19 severity. The association over time between them has not been assessed in a prospective cohort. Our aim was to evaluate the relationship between SARS-CoV-2 viremia and time evolution of IL6 levels in a COVID-19 prospective cohort. Methods: Secondary analysis from a prospective cohort including COVID-19 hospitalized patients from Hospital Universitario La Princesa between November 2020 and January 2021. Serial plasma samples were collected from admission until discharge. Viral load was quantified by Real-Time Polymerase Chain Reaction and IL6 levels with an enzyme immunoassay. To represent the evolution over time of both variables we used the graphic command Results: A total of 57 patients were recruited, with median age of 63 years (IQR [53-81]), 61.4% male and 68.4% Caucasian. The peak of viremia appeared shortly after symptom onset in patients with persistent viremia (more than 1 sample with > 1.3 log10 copies/ml) and also in those with at least one IL6 > 30 pg/ml, followed by a progressive increase in IL6 around 10 days later. Persistent viremia in the first week of hospitalization was associated with higher levels of IL6. Both IL6 and SARS-CoV-2 viral load were higher in males, with a quicker increase with age. Conclusion: In those patients with worse outcomes, an early peak of SARS-CoV-2 viral load precedes an increase in IL6 levels. Monitoring SARS-CoV-2 viral load during the first week after symptom onset may be helpful to predict disease severity in COVID-19 patients.

Indexed as

COVID-19interleukin 6 (IL-6)prognosisSARS-CoV-2viremia

Identifiers

PMID35783606
PMCPMC9240748
OpenAlexW4285743975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.